Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665629 | 0.86 | LMNA (0.55) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL26928039 | 0.85 | NPC1 (0.52) | LMNAALDH1A1KDM4EPKMNPC1 | |
| SCHEMBL26926832 | 0.85 | MAPK1 (0.49) | LMNAALDH1A1KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL20037188 | 0.84 | LMNA (0.66) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL21806760 | 0.83 | KDM4E (0.58) | LMNAALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL13172793 | 0.83 | NPC1 (0.51) | LMNAALDH1A1KDM4EPKMNPC1 | |
| SCHEMBL15656246 | 0.83 | ALDH1A1 (0.61) | LMNAALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL19086973 | 0.83 | MAPK1 (0.51) | LMNAALDH1A1KDM4EPKMNPC1 | |
| SCHEMBL25062617 | 0.82 | LMNA (0.58) | LMNAALDH1A1KDM4EPKMRAB9A | |
| SCHEMBL22118978 | 0.82 | TSHR (0.48) | LMNAALDH1A1KDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855260-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855260-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2712616-B1 | Intermediates for the preparation of 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection | DU PONT (US) | 2017-04-19 | — | — | EP | disclosed |
| CN-103517896-B | (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide | 葛兰素史密斯克莱有限责任公司 | 2016-09-21 | — | — | CN | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| EP-1448218-A4 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MED RES FOUND (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | OKLAHOMA MEDICAL RESEACH FOUNDATION (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1448218-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | Oklahoma Medical Research Foundation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2003039454-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003039454-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | LMNA 2562/4885ALDH1A1 1140/4885KDM4E 2470/4885 |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | BACE2, BACE1, PSEN2 | LMNA 470/4885ALDH1A1 4645/4885KDM4E 2181/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | LMNA 505/4885ALDH1A1 4517/4885KDM4E 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.